Research Article







ABSTRACT: Objectives: The goal of this study is to estimate autoimmune biomarkers that characterize the development and severity of arthritis, but probably normalize following successful therapy.
Materials and methods: In this study a total of 109 subjects were used out of which treated and untreated arthritics were 48 and 44 respectively, the remaining 17 were healthy individuals which were used as control. Samples were collected from patients attending Rheumatology and Orthopedic clinic of Federal Teaching Hospital Ido-ekiti, Ekiti State Nigeria. Antinuclear antibody was estimated using Enzyme Linked Immunosorbent Assay (ELISA) while Lupus Erythematosus cells were ascertained microscopically using Leishman staining technique. All parameters were assessed in treated and untreated arthritic patients relative to healthy subjects. Body mass index was also calculated. Statistical analysis was done using SPSS.  Results: Body mass index and Antinuclear antibodies were significantly higher in treated and untreated arthritics compared to control (P<0.05). When treated and untreated arthritics were compared, Body mass index and Antinuclear antibody were found to be significantly higher in untreated arthritics (P<0.05). Antinuclear antibody and Age correlated directly in untreated arthritics. Lupus Erythematosus cell prevalence was found to be higher in untreated arthritics having a percentage Lupus Erythematosus test positivity of 6.8% compared to the 2.1% seen in treated arthritics. Conclusion: It was found that Autoimmunity in arthritics can be significantly lowered through treatment with Arthritic drugs, diets, life style modifications over a period of time. The study suggests that Antinuclear antibody and Lupus Erythematosus estimations could be adopted as markers of diagnosis, prognosis and monitoring of arthritis.

Keywords: autoimmune biomarkers, ELISA, arthritics, Lupus Erythematosus


  1. [1]. Waite M. Oxford English Dictionary. OUP oxford 2012: p.35. ISBN  9780199640942

  2. [2]. Centre for Disease Control and Prevention. Adult BMI, from Centre for Disease Control and Prevention, “Arthritis Basics,” Retrieved August 10 2021 Retrieved August 10 2021

  3. [3]. Maetzel A, Li LC, Pencharz J, Tomlinson F, Bombardier C. The economic burden associated with osteoarthritis, rheumatic arthritis and hypertension: a comparative study. Annals Rheumatic Disease.63:395 – 401

  4. [4]. Lawrence RC, Felson DI, Helmick CG (2008). Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. Arthritis and Rheumatology. 2008 58(1):26 – 35.

  5. [5]. Felson DT. American college of rheumatology; European league against Rheumatism.            American college of Rheumatology/European League against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Arthritis and     Rheumatology 2011;63(3): 573- 586

  6. [6]. Perricone N Overview of Joint Anatomy and Physiology: A Basis for Understanding and   Assessing Rheumatic Conditions. 1984.https://                                               

  7. [7]. Wittenauer R, Smith L, and Aden K. Background Paper 6.12 Osteoarthritis .2013.  Available at

  8. [8]. Viswanath, D. Understanding Autoimmune Diseases- A Review. IOSR Journal of Dental and Medical Sciences.2013; 6.: 8-15. 10.9790/0853-0660815.

  9. [9]. Donath J, Landsteiner J. Ueberparoxys male Hamoglobinurie. Munch. Med Wschr 1904; 51:1590-93.

  10. [10]. Salamunic I. Laboratory diagnosis of autoimmune diseases-new technologies, old dilemmas. Biochemica lMedical.2010;20:45-56.

  11. [11]. Lernmark A. Autoimmune diseases: are markers ready for prediction? Journal on Clinical Investigation 2001;108: 1091-96.

  12. [12]. Thomas K, Juliane F, Heinz-Theodor M, Anne G. The Autoimmune Disease Database: a dynamically compiled literature-derived database. BMC Bioinformatics 2006; 7:325.

  13. [13]. Atkinson AJ, Colburn WA, DeGruttola VG, DeMets DL, Downing GJ, Hoth DF. Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework. Clinical Pharmacology and Therapeutics 2001;69: 89-95.

  14. [14]. Satoh M, Vázquez-Del Mercado M, Chan EK. Clinical interpretation of antinuclear antibody tests in systemic rheumatic diseases. Model Rheumatology 2009; 19:219-228.

  15. [15]. Kavanaugh A, Tomar R, Reveille J, Solomon DH, Homburger HA. "Guidelines for clinical use of the antinuclear antibody test and tests for specific autoantibodies to nuclear antigens. American College of Pathologists". Arch.Path. Lab. Med. 2000; 124:71–81.

  16. [16]. Klippel JH, Stone JH, Crofford LJ, White PH. Primer on Rheumatic Diseases. Thirteenth. Chapter 2. Springer; 2008. pp. 15–20.

  17. [17]. Hargraves MM, Richmond H, Morton R. Presentation of two bone marrow elements: the 'tart' cell and the "LE' cell. Proceedings of the Mayo Clinic.1948;23:25-28.

  18. [18]. Hanna T, Kari K, Tiina L, Herman W. Recommendation for indicators, international collaboration, protocol and manual operations for chronic disease risk factor surveys. (2002)

  19. [19]. Darshini DB, Rajesh J. Body weight perception and weight control practices among teenagers. International scholarly research notices Nutrition 2013;6: 395125.

  20. [20]. Eknoyan G. AdolpheQuetelet (1796-1874) the average man and indices of obesity, Nephrology Dialysis Transplantation. 2007;23: 47-51

  21. [21]. United states department for health and human servicesCentres for Disease Control and Prevention Retrieved August 10 2021

  22. [22]. Anandacoomarasamy A, Caterson I, Sambrook P, Fransen M, March L. The impact of obesity on the musculoskeletal system. Int J Obes (Lond) 2008; 32:211–22.

  23. [23]. Amine B, Ibn YY, Laatiris A, Wafki F. Prevalence of overweight in Moroccan patients with rheumatoid arthritis and its relationships with disease features. Clinical Rheumatology 2012; 31:479-482.

  24. [24]. Ajeganova S, Andersson ML, Hafstrom I. BARFOT Study Group. Association of obesity with worse disease severity in rheumatoid arthritis as well as withcomorbidities: A long term       follow up from disease onset. Arthritis Care Research.2013;65: 78-87

  25. [25]. Akilli H, Kayrak M, Bekci TT. Gender-related changes of the epicardial fat thickness and leptin  in obstructive sleep apnea. Echocardiol 2014; 31:411–9.

  26. [26]. Walravens M. Systemic disease and the detection of nuclear and anticytoplasmic antibodies. A historical review. Clinical Rheumatology. 1987;69-117.

  27. [27]. Criswell LA, Pfeiffer KA, Lum RF, Gonzales B, Novitzke J, Kern M, Moser KL, Begovich AB, Carlton VEH, Li W, Lee AT, Ortmann W, Behrens TW, Gregersen PK. Analysis of families in the Multiple Autoimmune Disease Genetics Consortium (MADGC) collection: the PTPN22 620W allele associates with multiple autoimmune phenotypes. American Journal of Human Genetics.2005;76:561–571 

  28. [28]. Zhernakova A, Eerligh P, Wijmenga C, Barrera P, Roep BO, Koeleman BP (2005). Differential association of the PTPN22 variant with autoimmune diseases in a Dutch population. Genes and Immunity.

  29. [29]. Hayashi N, Koshiba M, Nishimura K, Sugiyama D, Nakamura T, Morinobu S. Prevalence of disease-specific antinuclear antibodies in general population: estimates from annual physical examinations of residents of a small town over a 5-year period. Modern rheumatology / the Japan Rheumatism Association.2008;18:153–160.

  30. [30]. Grimaldi CM. Sex and systemic lupus erythematosus: the role of the sex hormones estrogen and prolactin on the regulation of autoreactive B cells. Current Opinion of Rheumatology.2006;18: 456-461.

  31. [31]. Oliver JE, Silman AJ. Why are women predisposed to autoimmune rheumatic diseases? ArthritisResearch and therapy.2009;11: 252.

  32. [32]. Monto RW, Rizek RA, Rupe CE, Rebuck JW. The L.E. Cell: Significance and relation To Collagen Disease the L.E. Cell: Significance and Relation to Collagen Disease. Henry Ford Hospital Medical Journal 1964; 12:389-94.

 To cite this article:

OO ODEWUSI, MJ ABDULMUMIN, OO OLANIYAN. An assessment of autoimmunity in arthritis patients. Int. J. Med. Lab. Res. 2022; 7, 1:53-61.